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Abstract  38 
 39 
Background: Studies suggest that anticholinergic medication or benzodiazepine use could 40 
increase dementia risk.  We tested this hypothesis using data from a UK cohort study. 41 
Methods: We used data from the baseline (Y0), 2-year (Y2) and 10-year (Y10) waves of the 42 
Medical Research Council Cognitive Function and Ageing Study. Participants without 43 
dementia at Y2 were included (n=8216). Use of benzodiazepines (including 44 
nonbenzodiazepine Z-drugs), anticholinergics with score 3 (ACB3) and anticholinergics with 45 
score 1 or 2 (ACB12) according to the Anticholinergic Cognitive Burden scale were coded as 46 
ever use (use at Y0 or Y2), recurrent use (Y0 and Y2), new use (Y2, but not Y0) or 47 
discontinued use (Y0, but not Y2).  The outcome was incident dementia by Y10.  Incidence 48 
rate ratios (IRR) were estimated using Poisson regression adjusted for potential 49 
confounders. Pre-planned subgroup analyses were conducted by age, sex and Y2 Mini-50 
Mental State Examination (MMSE) score. 51 
Results: Dementia incidence was 9.3% (N=220 cases) between Y2 and Y10.  The adjusted 52 
IRRs (95%CI) of developing dementia were 1.06 (0.72, 1.60), 1.28 (0.82, 2.00) and 0.89 (0.68, 53 
1.17) for benzodiazepines, ACB3 and ACB12 ever-users compared with non-users.  For 54 
recurrent users the respective IRRs were 1.30 (0.79, 2.14), 1.68 (1.00, 2.82) and 0.95 (0.71, 55 
1.28).  ACB3 ever-use was associated with dementia among those with Y2 MMSE>25 56 
(IRR=2.28 [1.32-3.92]), but not if Y2 MMSE≤25 (IRR=0.94 [0.51-1.73]). 57 
Conclusions: Neither benzodiazepines nor ACB12 medications were associated with 58 
dementia.  Recurrent use of ACB3 anticholinergics was associated with dementia, 59 
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particularly in those with good baseline cognitive function. The long-term prescribing of 60 
anticholinergics should be avoided in older people. 61 
 62 
Keywords: Alzheimer Disease, Cognition, Dementia, Cohort study, Benzodiazepines, 63 
Cholinergic Antagonists 64 
 65 
  66 
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Background 67 
 68 
Dementia prevention is a public health priority.  No disease modifying treatment for dementia exists, 69 
but dementia risk and progression can be modified by changing exposure to risk factors affecting any 70 
aspect of long-term brain health [1].  Identifying such risk factors is important for dementia 71 
prevention and cognitive health. 72 
Long-term use of several classes of medications have been suggested to increase future dementia 73 
risk.  Medications with anticholinergic activity (henceforth anticholinergics), benzodiazepines and 74 
related non-benzodiazepine derivatives have come under particular scrutiny owing to their well-75 
known short-term cognitive effects [2] and the high prevalence of their long-term use among middle 76 
aged and older people [3, 4].   77 
Anticholinergics are successfully used in the treatment of many conditions such as urinary 78 
incontinence, Parkinson’s disease, depression, and epilepsy.  Anticholinergics can adversely affect 79 
cognition [2]; guidelines suggest they are to be avoided among frail older people [5] or those with 80 
dementia [6]. Over the past decade, prolonged exposure to anticholinergics has been linked to long 81 
term cognitive decline or dementia [7–12].  Many medicines beyond those typically regarded as 82 
anticholinergics may have mild anticholinergic effects and it has been suggested that the cumulative 83 
long term use of many such medications may increase dementia risk [11].  Depending on their 84 
definition, anticholinergic medications are used by 10-50% of the middle aged and older population 85 
at any time [13, 14].   86 
Benzodiazepines and non-benzodiazepine derivatives are primarily used to treat anxiety or 87 
insomnia.  Short term cognitive effects due to their sedating action are well recognised.  Although 88 
long-term use is not recommended many people use regularly benzodiazepines and related 89 
medicines for years or decades [3]. Estimates of the effect of benzodiazepine use on long term 90 
cognitive decline and dementia have been mixed [15–22].   91 
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For both benzodiazepines and anticholinergics, several methodological biases exist in the published 92 
studies including first the lack of longitudinal observational window with a clear baseline 93 
measurement of cognitive and functional status of the population at risk; second the absence of gold 94 
standard measurement of the dementia incidence; third, no precise baseline measurement of the 95 
exposure variable (benzodiazepine and anticholinergic use); and finally the limitation of 96 
observational studies in resolving protopathic bias, whereby medication use might be prescribed for 97 
symptoms at the very early stages of dementia, inducing an association between medication use and 98 
later dementia diagnosis.   99 
We have previously demonstrated association between cognitive decline and anticholinergic use 100 
between baseline and 2-year follow-up assessments of the Medical Research Council Cognitive 101 
Function and Ageing Study (MRC CFAS) [9].  Here we extend this analysis to examine dementia 102 
incidence at 10 year follow-up, with respect to patterns of anticholinergic and benzodiazepine use at 103 
the baseline and 2-year follow-up assessments. 104 
Methods 105 
Setting 106 
The MRC CFAS is a population based, prospective, multicentre cohort study in England and Wales 107 
specifically designed to estimate the prevalence, risk factors and course of dementia. The study 108 
design has been described elsewhere [23]; (see also www.cfas.ac.uk for full details).  109 
 110 
In brief, 13004 participants, age 65 and older, from Cambridgeshire, Gwynedd, Newcastle, 111 
Nottingham and Oxford, were recruited with baseline interviews (Y0) conducted between 1991 and 112 
1993. All individuals still alive and traceable were invited to be re-interviewed at two years (Y2) and 113 
10 years (Y10) after baseline. At each wave, participants were questioned about sociodemographic 114 
factors, lifestyle, physical and mental health (including self-reported insomnia, measures of anxiety 115 
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and depression) and completed a cognitive battery and in-home medication inventory. For the 116 
present analysis, we included all those who participated at Y2 with no study diagnosis of dementia at 117 
Y0 or at Y2, and measured incident dementia as an outcome at Y10. 118 
Outcome assessment 119 
At Y0 and Y2 the study diagnosis of dementia was made using a two-phase process (Figure 1).  An 120 
initial screening interview was administered to all participants.  A stratified subsample of 20%, 121 
including all of those with cognitive impairment, but also including healthy participants then 122 
underwent a thorough assessment using the Automated Geriatric Examination for Computer 123 
Assisted Taxonomy (AGECAT) algorithm to make a study diagnosis of dementia (23,24,25). AGECAT 124 
produces a score of between 0 and 5. Dementia was defined as AGECAT scores ≥ 3 which is 125 
equivalent to dementia as diagnosed by DSM-III-R (23)   All surviving participants underwent the full 126 
assessment at Y10. 127 
For those who underwent a screen interview but were not selected to undergo the assessment we 128 
imputed the Y2 dementia status based on cognitive screen scores (using a multiple imputation).  This 129 
procedure identified that there were possibly a small number of cases of dementia among the 130 
screen-only sample, but these were only very rarely seen among those surviving Y10 sample. Hence 131 
our primary analysis assumed no prevalent dementia cases among the Y2 screen-only participants; 132 
participants who were imputed to have dementia at baseline were excluded in a sensitivity analysis. 133 
Medication Exposures  134 
During each interview participants were asked to provide details of all medication currently being 135 
used, either prescribed or bought over-the-counter.  These were recorded using UK National Health 136 
Service Read codes. Packaging was checked and proxy respondents supplied medication information 137 
if participants were unable to do so.  Previous studies in older population have demonstrated self-138 
reported medication data gathered in this way to be mostly in moderate-good agreement with 139 
prescription data records [27]. 140 
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All medications were coded according to the Anticholinergic Cognitive Burden (ACB) scale [28].  In 141 
summary, medications with serum anticholinergic activity or in vitro affinity to muscarinic receptors 142 
but with no known clinically relevant negative cognitive effects are scored 1 on the scale, while 143 
drugs with established and clinically relevant anticholinergic effects are scored 2 based on blood-144 
brain penetration and 3 if also have reported associations with delirium.  All other drugs are scored 145 
0.  Very few medications were classed as having an ACB score of 2, so we created binary exposure 146 
variables for at , ACB12 (use of any medications scoring 1 or 2) and ACB3 (use of any medications 147 
scoring 3).  A total ACB sum score, and a variable corresponding to the sum of ACB12 drugs only was 148 
also created at.  Each of these exposures was determined independently at Y0 and Y2. 149 
Similarly for benzodiazepines, at a binary variable (BZD) corresponding to taking any benzodiazepine 150 
or non-benzodiazepine derivative (hypnotics such as zopiclone also known as Z-drugs) was created 151 
at both Y0 and Y2. 152 
For each group (BZD, ACB12 and ACB3) participants were then classified as being an ‘ever-user’ (if 153 
there was any use at Y0 or Y2), and then sub-classified as a ‘recurrent user’ (use at Y0 and Y2) new 154 
user (only at Y2), or as a discontinuing user (only at Y0). 155 
Covariates 156 
We selected covariates that might have a confounding effect between the use of benzodiazepines or 157 
anticholinergics and incident dementia. We included demographic variables of sex, age, education (≤ 158 
9 years, ≥ 10 years), social class (measured by prior occupation as manual vs non manual), centre of 159 
recruitment, and study arm (screen or assessment),  variables that are indicators for ACB3 or BZD 160 
use, early symptoms of dementia or known to be associated with dementia (reporting having 161 
suffered stroke, Parkinson disease, epilepsy, sleep problems, anxiety, depression or being diagnosed 162 
depression at either Y0 or Y2, as binary variables), self- reported health (excellent/good; fair/poor) at 163 
Y2 and cognition related variables. 164 
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Pre-existing cognitive impairment and ongoing cognitive decline are the most important potentially 165 
confounding factors, these were measured by the Mini-Mental State Examination (MMSE) at Y2 166 
(≤25, >25), the decrease in MMSE scores between Y0 and Y2 (<1, 1, 2 ≥3 points), the MMSE 167 
orientation sub-score at Y2 (<9, 9/10) and self-perceived change in memory function between 168 
recruitment and 2 years (No change or better vs worse).  Disability at Y2 was classified using the 169 
Townsend disability scale as either no impairment, any impairment in instrumental activities of daily 170 
living or any impairment in basic activities of daily living [29].  171 
Statistical analyses 172 
Separate univariable Poisson regression models with Huber-White robust standard errors were used 173 
to estimate incident rate ratios (IRR) for the association between each potential predictor variable 174 
and incident dementia at Y10 [30].  95% confidence intervals are reported for all estimates.  175 
In multivariable analysis we additionally included each of the three ever-use variables (where they 176 
were not the exposure of interest) and the demographic, health and cognition related variables 177 
mentioned above. 178 
We carried out pre-planned stratified analyses of the main ‘ever-use’ models by year of birth (≤1919 179 
vs 1920 onwards), sex and MMSE score at Y2 (>25, ≤25).  The threshold for cognitive function and 180 
age were chosen as they reflect the stratification of the original CFAS study sampling. 181 
As expected in this population there was substantial loss to follow-up between Y2 and Y10 caused by 182 
drop out and death.  Inverse probability weights were used to adjust for non-response at Y10 and 183 
loss of contact between Y2 and Y10 or refusal to participate at Y10, conditional on having survived.  184 
These weights were calculated using a logistic regression model for being successfully re-assessed at 185 
W10 (conditional on surviving to W10) including the main effects of all exposures (BZD, ACB12 and 186 
ACB3), covariates and the interactions between exposures and sex and MMSE at Y2. 187 
STATA 14.1 was used for all analysis. 188 
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 189 
Sensitivity analyses 190 
We carried out three sensitivity analyses to test the impact of modelling assumptions or analytical 191 
choices on our results.  First, we excluded potentially mediating or colliding variables of: MMSE at 192 
Y2, change in MMSE (Y0 to Y2), MMSE orientation sub-score at Y2, disability, and arm of the study.   193 
Second, we used multiple imputation to identify screen-only participants with dementia at baseline 194 
based on their demographic information and cognitive scores as described above, and excluded 195 
them from each imputed analysis. Finally, we took into account the possibility that higher mortality 196 
rates among older people taking anticholinergics or benzodiazepine and related medications might 197 
suppress our estimates of dementia incidence in this group via inverse probability weights calculated 198 
using on the probability of death or drop-out (rather than drop-out alone) between Y2 and Y10 199 
based on baseline factors. 200 
 201 
Results 202 
 203 
See Figure 1 for participant flow through the study.  From the 13004 participants recruited to MRC 204 
CFAS at Y0, 8216 were interviewed at Y2, did not have dementia or unknown dementia status at Y2 205 
and so form the baseline sample for our incidence analysis.  Of these, 3136 died and 1990 were lost 206 
to follow up before Y10. At Y10, we excluded further 5 participants classified as having dementia in 207 
Y0 but not Y10 and 45 with unknown dementia status at Y10, leaving 220 people with incident 208 
dementia and 2825 people without incident dementia included in the study. 209 
<Insert figure 1> 210 
Table 1 shows participant characteristics stratified by follow-up status. Those who developed 211 
dementia by Y10 were older, had lower cognitive function at Y2 (mean MMSE 24 vs 27), more 212 
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disability (ADL-IADL 22% vs 7%), fewer years of education (≥ 10 years 29% vs 44%) and were 213 
substantially more likely to report worsening memory from recruitment to 2-year follow up (44% vs 214 
29%) and poorer health (32% vs 21%).  215 
<insert table 1> 216 
Medication use 217 
A breakdown of baseline exposures by 10-year follow-up status is shown in Table 1.  Full details of 218 
drug use are in Additional file 1.  Among those surviving to 10 years, 7.5% reported ever use of a BZD 219 
(short-acting 4.2%, long-acting 3.7%).  Hypnotic BZD were used by 5.9% with 1.9% using anxiolytics.  220 
The most commonly reported BZDs were Temazepam (47% of BZDs reported), Nitrazepam (30%) 221 
and Diazepam (15%).  Non-benzodiazepine Z-drug use was rare in this cohort (prevalence of 0.4%). 222 
Use of ACB3 at baseline or 2-year follow-up was reported by 5.6% of the surviving sample; 2.3% 223 
were recurrent users.  The majority of ACB3 drugs were antidepressants (3.8% of the surviving 224 
sample; corresponding to 69% of ACB3 medications), urologicals (0.7% reported ever use among the 225 
sample), gastrointestinal (0.6%), antipsychotics (0.5%), antihistamines (0.3%) and Parkinsonian drugs 226 
(0.1%).   The most common ever-use ACB3 medications were the antidepressants: amitriptyline (22% 227 
of ACB3) and dosulepin (22% and of ACB3).  228 
In total, 53% of the surviving sample reported ACB1 or ACB2 at baseline or 2-year follow-up, with 229 
34% reporting ACB1 or ACB2 use at both waves. 230 
Although Y10 medication is not considered an exposure in our study, we compared Y10 to Y0 and Y2 231 
medication to understand to what extent medication use was likely to have continued in the overall 232 
study sample.  Medication use at Y10 was highly correlated with use at Y0 and Y2 (see Additional file 233 
2) with around 60% of ‘recurrent’ users at Y0 and Y2 reported use of each class at Y10.  This suggests 234 
that in many cases use at Y0 and Y2 is likely to reflect repeated use during the follow-up period as 235 
opposed to being one-off exposures. 236 
Page 12 of 29 
 
 237 
Dementia incidence  238 
Table 2 describes incident dementia in our sample as well as the unadjusted and adjusted incidence 239 
rate ratios (aIRR). After weighting, 9.5% (N=220) of participants had a study diagnosis of dementia at 240 
Y10; 14.5%, 15.4% and 10.5% for BZD, ACB3, ACB12 ever-users and 16.0%, 18.6% and 10.7% for 241 
recurrent users, respectively.    242 
Adjusted IRRs for dementia at Y10 were 1.06 (95%CI 0.72, 1.60) for any BZD use, 1.28 (95% CI 0.82, 243 
2.00) for any ACB3 and 0.89 (95%CI 0.68 1.17) for any ACB12 use.  Recurrent use was associated with 244 
IRRs of 1.30 (95%CI 0.79, 2.14) for BZD, 1.68 (95%CI 1.00, 2.82) for ACB3 and 0.95 (95%CI 0.71, 1.28) 245 
for ACB12.   246 
There was no evidence for an increase in dementia risk with increasing total ACB score at each wave, 247 
or with the number of ACB1 or ACB2 medications used. No significant association was found 248 
between dementia and ever-use of short or medium-acting, long-acting, hypnotic or anxiolytic BZDs, 249 
or for anti-depressant or ‘other’ anticholinergics although numbers in these subgroups were small 250 
(results not shown). 251 
<insert table 2> 252 
 253 
Stratified analysis 254 
Stratified analyses are shown in Table 3.   The effect of ACB3 was restricted to those with good 255 
baseline cognitive function (ever-users aIRR: 2.28, 95%CI 1.32, 3.92), whereas no such association 256 
was seen among the group with impaired cognition (ever-users aIRR: 0.94, 95% CI: 0.51-1.73).  Those 257 
with poor cognitive function (MMSE ≤25 at Y2) had a dementia incidence rate of around 21% 258 
irrespective of anticholinergic use (21.3%; 97 of 500 among never-users vs 21.8%; 9 of 46 for ever-259 
users), while for those with good cognitive function (MMSE>25 at Y2) the Y10 dementia incidence 260 
rate was 11.1% (13 of 124) for ACB3 ever-users and 4.7% (101 of 2326) for never-users (Additional 261 
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file 3).  This is supported by a statistically significant interaction effect (p=0.02).  No other significant 262 
subgroup differences were found. 263 
<insert table 3> 264 
Sensitivity analyses 265 
Results from the sensitivity analyses are shown in Additional file 4. No changes were seen after 266 
removing imputed possible dementia cases at baseline or 2-year follow-up. However, after excluding 267 
baseline disability and cognition related variables from multivariable regression there was a small 268 
increase in the effects of any ACB3 use and recurrent use with aIRRs 1.55 (95%CI 1.04, 2.32) and 2.02 269 
(95%CI 1.21, 3.39), respectively. No main changes were observed when using weights to adjust for 270 
mortality or after carrying out a competing risk analysis (results not shown).  In analysis stratified by 271 
cognitive score, there is no change to main findings in sensitivity analysis; for example when using 272 
inverse probability weights to adjust for attrition by death or other loss to follow up the association 273 
between baseline ACB3 use and incident dementia among those with MMSE>25 at W2 is aIRR=2.24 274 
(95% CI: 1.24-4.06) compared to IRR=1.01 (0.55-1.87) among those with W2 MMSE<25. 275 
 276 
Discussion 277 
In a cohort study with 10-year follow-up we did not find any evidence of an increase in risk of 278 
dementia associated with the use benzodiazepines or anticholinergics scoring ACB1 or ACB2.  We did 279 
find a statistically significant increase in dementia risk among recurrent users of ACB3 280 
anticholinergics and also an association between ACB3 anticholinergics use and dementia risk among 281 
the subgroup with good baseline cognitive function, suggesting that effects might more apparent in 282 
different subgroups of the older population. 283 
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Benzodiazepines 284 
Previous studies on the effect of benzodiazepines have been inconsistent, with some large and 285 
apparently high quality studies showing a clear effect of benzodiazepine use on dementia incidence 286 
[16–18, 20, 21], but others finding no effect [15, 19, 30].   There is no readily apparent difference 287 
between these studies in design that explains this inconsistency, although possible explanations 288 
include selection biases into electronic health record databases, differing methods of ascertaining 289 
benzodiazepine use, such as duration, dose and chronicity and the measurement of dementia 290 
outcome [15], or the differing profile of benzodiazepine use [31], population characteristics across 291 
studies or the manner in which each study was able to control for covariates.    There was 292 
insufficient use of Z-drugs among our cohort to draw any conclusions regarding their effects on 293 
dementia incidence. 294 
Strong anticholinergics  295 
Our estimate of the effect of ACB3 anticholinergics on dementia incidence was not statistically 296 
significant, but is consistent with recent effect estimates from analyses of electronic medical records 297 
[7, 32].  However, in planned subgroup analyses we observed a borderline significant increased 298 
dementia risk in recurrent users of ACB3 anticholinergics, defined as those participants who 299 
reported anticholinergic use at both baseline and two-year follow-up, more likely to reflect a longer 300 
term or continuous anticholinergic load.  This is consistent with the hypothesis that long-term as 301 
opposed to one-off use is needed to increase dementia risk. 302 
 303 
Consistent with our work, previous studies have consistently reported associations between 304 
anticholinergic use and dementia incidence, with a greater effect seen among prevalent (as opposed 305 
to new users) or long-term recurrent users, with some studies reporting a dose effect with 306 
increasing risk at higher doses [7, 32]. New use or short term use has consistently not been 307 
associated with risk of developing dementia [8]. Similar results have been observed for studies 308 
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focussing on cognitive change instead of dementia or MCI outcomes and in neuropathology studies 309 
[33, 34]. 310 
We stratified our analysis by baseline cognitive function to test the hypothesis that the effect is only 311 
seen among people with an existing cognitive impairment, reflecting possible protopathic bias.  In 312 
fact the reverse was observed, the effect was restricted to those with good baseline cognitive 313 
function.  It is possible that this reflects increased attrition among the more cognitively frail using 314 
anticholinergics, however this finding is not affected by using a weight that corrects for attrition due 315 
to death, and in any case this results demonstrates that the increase in dementia incidence 316 
associated with anticholinergics is not restricted to those with existing cognitive impairment or those 317 
with incipent dementia. 318 
Anticholinergics represent a broad class of medications that act on different systems, and it is 319 
possible that different anticholinergics have different long term effects on brain health [12].  320 
Disaggregation of anticholinergic classes may also help to identify possible confounding by indication 321 
or protopathic bias.    Our study suggests that anticholinergics other than antidepressants have a 322 
stronger link with incident dementia than do anticholinergic antidepressants after adjustment for 323 
confounding factors, but owing to small numbers estimates of the effects of subclasses are very 324 
imprecise  [7, 12]. 325 
 326 
Anticholinergics with score of 1 or 2 327 
While ACB3 anticholinergics are used by only 3-5% of the older population at any time, up to 50% 328 
are using one or more of the much wider group that are considered ‘possibly’ anticholinergic (score 329 
of 1), and any effect of these medications on dementia incidence would have a great public health 330 
significance [9].  Our finding that the number of ACB12 anticholinergics used is not associated with 331 
future incident dementia agrees with our previous analysis of cognitive change between baseline 332 
and 2 years [9] and previous studies that have considered these groups separately [12, 35, 36]. The 333 
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number of medications classified as ACB2 is very small and this effect estimate is largely dominated 334 
by the effect of medications classified ACB1. Findings from the Baltimore Longitudinal Study of 335 
Ageing suggest an increase in the risk of ‘Alzheimer’s disease or MCI’ with increasing use of ‘possible’ 336 
anticholinergics, with an associated increase in cortical atrophy, although there was no effect of 337 
definite anticholinergic (score of 3) use suggesting that anticholinergic properties of these drugs may 338 
not underlie the effect [37]. 339 
 340 
Strengths and limitations 341 
Our study has several important strengths and limitations.  By using the first two waves of MRC CFAS 342 
(years 0 and 2) as the baseline and dementia at 10-year follow-up as the outcome we could identify 343 
the long-term effect of different patterns of uses of medications in a population-representative 344 
cohort.  We did not measure medication use or dementia diagnoses occurring between assessments, 345 
or the diagnoses for those who dropped out before Y10.  Although the high concordance between 346 
medications used at Y0, Y2 and Y10 suggests that use was may have been continual during the follow 347 
up period in many cases, we have no direct evidence for this. Medication use was based on self-348 
report and adherence was not formally assessed; although there is no gold standard method for 349 
measuring adherence to medication [38].  Dementia was measured using a validated algorithm, and 350 
thus any bias due to outcome ascertainment is reduced compared to studies relying on a recorded 351 
diagnosis dementia which will significantly under represent true dementia incidence [39]. 352 
 353 
Despite the large sample size of MRC CFAS (n=13004), the numbers using benzodiazepines or 354 
anticholinergics with score ACB3 during the first two waves and developing incident dementia by 355 
Y10 are relatively small.  Estimating effects for subgroups is difficult.  Attrition over 8 years was 356 
typical of that seen in comparable studies of ageing, and we applied inverse probability weighting 357 
based on exposures and baseline cognitive scores to adjust for differential drop-out. Use of inverse 358 
probability weights assumes that loss to follow-up or death was not differential with respect to 359 
Page 17 of 29 
 
unmeasured confounders or to the outcome. Our findings might be biased if the interaction 360 
between medication use and dementia has a specific association with drop-out that could not be 361 
attributed to either factor alone or the interaction between exposure and pre-existing cognitive 362 
impairment. 363 
 364 
We controlled for many relevant potential confounders, in particular for many of the indications for 365 
anticholinergics and benzodiazepines.  We could not control for urinary incontinence or obesity as 366 
this was not routinely recorded, however the anticholinergic urologicals were rarely used among this 367 
cohort.  Mental health disorders apart from depression and anxiety were also not routinely 368 
recorded.  Adjusting for recent cognitive decline and observing the effect among those with good 369 
cognitive function at Y2 helps to exclude the possibility of protopathic bias due to reverse causation. 370 
 371 
Conclusions 372 
We found no evidence that benzodiazepines are associated with dementia incidence but we cannot 373 
rule out an effect as the number of benzodiazepine users in our study was relatively small.  374 
Consistent with previous studies we found an increase in dementia incidence associated with the 375 
recurrent use of anticholinergics with an ACB score of 3, particularly among those with good 376 
baseline cognitive function.  This should be treated with caution owing to small sample size but 377 
when considered alongside the growing body of evidence from cohort studies and administrative 378 
data sources suggests that at least some anticholinergic medications could increase the risk of future 379 
dementia.  The prevalence of anticholinergic medication use remains high among middle aged and 380 
older people, making this a potentially important modifiable risk factor for dementia.  Future 381 
research should focus on more carefully establishing the mechanism by which this occurs, whether 382 
the effect is reversed by medication cessation and whether specific anticholinergic medication or 383 
classes of medication confer the greatest risk and among which subgroups of the population. 384 
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Table 1. Participant characteristics stratified by Y10 follow-up status and dementia outcome 531 
 532 
Characteristic  
Dementia at 
Y10 (n=220) 
No dementia 
at Y10 
(n=2,825) 
Lost to follow 
up 
between Y2 
and Y10 
(n=1,990) 
Died 
between Y2 
and Y10 
(n=3,136) 
Female  163 (77.3) 1675 (61.2) 1315 (66.1) 1630 (52.0) 
Mean age (SD)  77.1 (7.0) 72.0 (10.0) 73.8 (6.1) 76.9 (6.7) 
Educated for ≥9 years 68 (29.3) 1311 (43.9) 754 (37.9) 1127 (35.9) 
Manual occupation 132 (61.7) 1359 (50.1) 1088 (54.7) 1751 (55.8) 
CFAS assessment arm 84 (51.0) 594 (27.4) 814 (40.9) 999 (31.9) 
Y2 MMSE ≤21 30 (22.6) 57 (3.5) 190 (9.6) 381 (12.2) 
 22-25 76 (38.4) 432 (20.0) 552 (27.7) 845 (27) 
 26-30  114 (39.0) 2336 (76.5) 1196 (60.1) 1847 (58.9) 
Decline in MMSE 
between Y0 and 
Y2 
No decline / 
improvement 100 (41.1) 1592 (55.0) 988 (49.6) 1444 (46.0) 
1 point 34 (13.1) 529 (17.6) 302 (15.2) 487 (15.5) 
2 points 34 (13.6) 350 (11.8) 220 (11.1) 364 (11.6) 
≥3 points 50 (29.0) 326 (14.2) 402 (20.2) 729 (23.2) 
Disability None  121 (47.1) 2336 (80.0) 1386 (69.6) 1562 (49.8) 
 IADL impairment 65 (30.2) 350 (13.1) 331 (16.6) 672 (21.4) 
 
ADL impairment / 
unclassified 34 (22.7) 139 (7.0) 273 (13.7) 902 (28.8) 
Self-reported memory decline (Y0 to Y2) 110 (48.7) 774 (27.4) 592 (29.7) 1152 (36.7) 
Fair/poor self-reported health 66 (31.7) 529 (21.2) 523 (26.3) 1174 (37.4) 
Comorbiditya Sleep disturbance 56 (26.5) 606 (22.6) 507 (25.5) 902 (28.8) 
 Diagnosed depression 22 (11.0) 309 (11.3) 216 (10.9) 290 (9.2) 
 
Consulted GP for 
depression 31 (15.8) 388 (14.4) 282 (14.2) 387 (12.3) 
 
Consulted GP for 
anxiety 28 (11.8) 242 (8.5) 186 (9.3) 228 (7.3) 
BZD useb None 195 (86.6) 2623 (91.7) 1763 (88.6) 2726 (86.9) 
 Any e  25 (13.5) 202 (8.3) 222 (11.2) 391 (12.5) 
 New f 5 (2.2) 43 (1.9) 49 (2.5) 92 (2.9) 
 Discontinuing g 6 (3.2) 51 (2.0) 57 (2.9) 95 (3.0) 
 Recurrent h 14 (8.1) 108 (4.4) 116 (5.8) 204 (6.5) 
ACB3 usec None 198 (89.8) 2677 (94.1) 1842 (92.6) 2831 (90.3) 
 Any e  22 (10.2) 148 (5.9) 143 (7.2) 286 (9.1) 
 New f 5 (1.8) 55 (2.2) 58 (2.9) 112 (3.6) 
 Discontinuing g 5 (3.6) 35 (1.5) 43 (2.2) 78 (2.5) 
 Recurrent h 12 (4.9) 58 (2.2) 42 (2.1) 96 (3.1) 
ACB12 used None 85 (41.0) 1353 (47.3) 908 (45.6) 972 (31) 
 Any e  135 (59.0) 1472 (52.7) 1077 (54.1) 2145 (68.4) 
 New f 34 (16.0) 321 (11.4) 210 (10.6) 419 (13.4) 
 Discontinuing g 11 (4.5) 209 (7.9) 175 (8.8) 327 (10.4) 
 Recurrent h 90 (38.5) 942 (33.5) 692 (34.8) 1399 (44.6) 
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 533 
Number of participants (percentages) given unless specified otherwise. Estimated number and 534 
percentage of participants at Wave 10 are weighted for attrition due to non-response at Wave 10 535 
and loss of contact between Wave 2 and Wave 10 536 
 537 
Abbreviations: CFAS = Cognitive Function and Ageing Study, SD = standard deviation; MMSE = 538 
Mini-Mental State Examination, IADL= Instrumental Activities of Daily Living ADL= Activities of 539 
Daily Living, GP=General Practitioner 540 
 541 
a Any record of specific comorbidity at the Y0 or Y2 assessment  542 
b Use of benzodiazepines or Z-drugs  543 
c Use of drugs scoring 3 on the Anticholinergic Cognitive Burden scale  544 
d Use of drugs scoring 1 or 2 on the Anticholinergic Cognitive Burden scale 545 
e-h Drug use categories are  546 
None: no use at Y0 or Y2;  547 
Any: Use at Y0 or Y2;  548 
New: Use at Y2 but not Y0 549 
Discontinuing: Use at Y0 but not Y2 550 
 551 
  552 
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Table 2. Attrition-weighted unadjusted and multivariable adjusted incidence rate ratios for the 553 
association between benzodiazepine and anticholinergic medication use and incident dementia  554 
 555 
Exposure and pattern of use 
Dementia incidence  
Unadjusted IRR  
(95% CI) Adjustedb IRR (95% CI) Cases Total  %a 
BZD use      
None 195  2819 9.0 1 (Ref.) 1 (Ref.) 
Any 25 227 14.5 1.61 (1.06,2.46) 1.06 (0.72,1.60) 
New  5 48 11.1 1.23 (0.51,2.96) 0.65 (0.27,1.60) 
Discontinuing 6 57 14.1 1.57 (0.74,3.35) 1.06 (0.53,2.14) 
Recurrent 14 122 16.0 1.78 (1.02,3.12) 1.30 (0.79,2.14) 
ACB3 use      
None 198 2876 9.1 1 (Ref.) 1 (Ref.) 
Any 22 170 15.4 1.70 (1.09,2.65) 1.28 (0.82,2.00) 
New  5 60 7.9 0.88 (0.37,2.09) 0.87 (0.34,2.22) 
Discontinuing 5 40 20.1 2.22 (0.96,5.14) 1.19 (0.53,2.68) 
Recurrent 12   70 18.6 2.05 (1.18,3.56) 1.68 (1.00,2.82) 
ACB3 subclass      
Not antidepressants 6 53 13.6 1.50 (0.68,3.32) 1.74 (0.84,3.62) 
Antidepressants 16 117 16.1 1.78 (1.06,2.98) 1.16 (0.69,1.94) 
ACB1 or ACB2 use      
None 85 1438 8.3 1 (Ref.) 1 (Ref.) 
Any 135 1609 10.5 1.26 (0.95,1.67) 0.89 (0.68,1.17) 
New  34 355 12.8 1.54 (1.02,2.33) 1.14 (0.79,1.63) 
Discontinuing 11 220 5.6 0.68 (0.36,1.27) 0.36 (0.19,0.69) 
Recurrent 90 1033 10.7 1.29 (0.95,1.75) 0.95 (0.71,1.28) 
ACB sum score   
Total ACB score (per point) 1.07 (1.03,1.13) 1.00 (0.94,1.06) 
ACB12 score (per point) 1.06 (1.00,1.13) 0.97 (0.90,1.04) 
ACB3 score (per point) 1.10 (1.02,1.19) 1.06 (0.98, 1.15) 
 556 
Abbreviations: IRR, Attrition-weighted unadjusted incidence rate ratio; aIRR, Attrition-weighted 557 
adjusted incidence rate ratio; CI, confidence-interval; ACB=Anticholinergic Cognitive Burden; ACB1 =  558 
use of a medicine with an ACB score of 1.  Scores correspond to possibly anticholinergic (score 1) 559 
probably anticholinergic (score 2) definitely anticholinergic (score 3).  560 
a % represents weighted incidence 561 
b Adjusted for sex, age, education (≤ 9 years, ≥ 10 years), social class (manual vs non manual), 562 
residential accommodation, centre of recruitment, study arm (screen or assessment),  health 563 
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conditions at Y0 or Y2 (stroke, Parkinson disease, epilepsy, sleep problems, anxiety, depression), self- 564 
reported health (excellent/good; fair/poor) at Y2, Disability at Y2 (no impairment, impairment in 565 
instrumental activities of daily living, or impairment in basic activities of daily living), Mini-Mental 566 
State Examination (MMSE) at Y2 (≤25, >25), MMSE orientation sub-score at Y2 (<9, 9/10), decrease 567 
in MMSE score between Y0 and Y2 (<1, 1, 2 ≥3 points), and self-perceived change in memory 568 
function between Y0 and Y2 (No change or better vs worse).   569 
  570 
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Table 3. Attrition-weighted adjusted incidence rate ratios for benzodiazepine and anticholinergic 571 
medication use and incident dementia, stratified by cognition, sex and age 572 
 Incidence rate ratio (95% confidence interval) by exposure 
Subgroup Any Benzodiazepines 
 
Any ACB3 Any ACB12 
MMSE at Y2 >25 0.72 (0.35,1.50) 2.28 (1.32,3.92)* 0.99 (0.68,1.43) 
MMSE at Y2 ≤25 1.23 (0.74,2.06) 0.94 (0.51,1.73) 0.78 (0.54,1.12) 
Male 0.29 (0.06,1.31) 2.06 (0.78,5.46) 1.11 (0.66,1.89) 
Female 1.17 (0.77,1.78) 1.24 (0.77,2.01) 0.85 (0.63,1.16) 
Younger (born 1920-1929) 1.31 (0.52,3.27) 1.16 (0.45,3.01) 1.57 (0.82,3.00) 
Older (born before 1920) 1.06 (0.69,1.61) 1.27 (0.78,2.09) 0.77 (0.58,1.03) 
 573 
* p<0.01 574 
 575 
Abbreviations: MMSE, Mini-Mental State Examination; ACB, Anticholinergic Cognitive Burden; 576 
 ACB12 = use of a medicine with an ACB score of 1 or 2.  Scores correspond to possibly 577 
anticholinergic (score 1), probably anticholinergic (score 2) and definitely anticholinergic (score 3).  578 
Number of observations and adjusted percentage in each group are reported in additional file 3. 579 
   580 
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 581 
 582 
Figure 1 – Flow of participants included in the current analysis through the MRC Cognitive Function 583 
and Ageing Study.  See www.cfas.ac.uk for the full design of the Cognitive Function and Ageing 584 
Studies. 585 
